A TWO-SITE IMMUNOASSAY WILL BE DEVELOPED AGAINST APOLIPO- PROTEIN A-I (APOA-I), THE MAJOR APOPROTEIN OF HIGH-DENSITY LIPOPROTEIN (HDL).

A TWO-SITE IMMUNOASSAY WILL BE DEVELOPED AGAINST APOLIPO- PROTEIN A-I (APOA-I), THE MAJOR APOPROTEIN OF HIGH-DENSITY LIPOPROTEIN (HDL). LOW LEVELS OF APOA-I HAVE BEEN POSITIVELY CORRELATED WITH CORONARY ARTERY DISEASE (CAD). TO ENSURE ADEQUATE QUANTIFICATION, CYANOGEN BROMIDE (CNBR) FRAGMENTS OF APOA-I WILL BE USED TO GENERATE MONOCLONAL ANTIBODIES (MABS), WHICH WILL BE SELECTED TO RECOGNIZE SEPARATE EPITOPES ON THE SOLUBLE PROTEIN IN UNTREATED PLASMA. THE ASSAY SYSTEM USED WILL BE THE ENZYME-LINKED IMMUNOSORBANT ASSAY (ELISA). QUANTITATIVE RESULTS FROM THE ELISA WILL BE CORRELATED WITH OTHER IMMUNOASSAYS AND WITH ASSAYS BASED ON DIRECT MEASUREMENT OF PROTEIN MASS. THE ULTIMATE GOAL WILL BE TO DEVELOP ELISA KITS FOR RESEARCH ANDCLINICAL MEASUREMENT OF THIS IMPORTANT CAD RISK FACTOR.